Methods and dosage forms for controlled delivery of paliperidone and risperidone
    2.
    发明申请
    Methods and dosage forms for controlled delivery of paliperidone and risperidone 审中-公开
    受控输送帕培培酮和利培酮的方法和剂型

    公开(公告)号:US20050232995A1

    公开(公告)日:2005-10-20

    申请号:US11051165

    申请日:2005-02-04

    摘要: Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

    摘要翻译: 提供了用于提供帕培酮或利培酮的基本上升释放速率的剂型和方法。 当每天施用一次时,持续释放剂型提供治疗有效的平均稳态血浆普利培酮或利培酮浓度。 这种每天一次的给药方案导致每24小时内出现一次峰值血浆普利培酮或利培酮浓度。 此外,剂量给药后的较晚时间,峰值血浆普利培酮或利培酮浓度发生在比立即释放剂型给药帕立哌酮或利培酮后出现的峰值血浆普利培酮或利培酮浓度更小的程度。

    Methods and dosage forms for reducing side effects of carbamate compounds
    9.
    发明申请
    Methods and dosage forms for reducing side effects of carbamate compounds 审中-公开
    减少氨基甲酸酯化合物副作用的方法和剂型

    公开(公告)号:US20070004797A1

    公开(公告)日:2007-01-04

    申请号:US11478241

    申请日:2006-06-29

    IPC分类号: A61K31/325

    摘要: Disclosed are dosage forms and methods comprising compounds of Formula (I) and Formula (II). More particularly, disclosed are dosage forms, methods, and new uses of compounds of Formula (I) and Formula (II) that substantially reduce or substantially eliminate certain side effects of the compounds of Formula (I) and Formula (II) when dosed to a patient.

    摘要翻译: 公开了包含式(I)和式(II)的化合物的剂型和方法。 更具体地,公开了式(I)和式(II)化合物的剂型,方法和新用途,其在给予式(I)和式(II)化合物时基本上减少或基本上消除了式(I)和式(II)化合物的某些副作用 病人。